Treatment for Completers of the Study B7A-MC-MBCM

Status:

COMPLETED

Treatment for Completers of the Study B7A-MC-MBCM

Lead Sponsor:

Chromaderm, Inc.

Conditions:

Diabetic Retinopathy

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment...

Eligibility Criteria

Inclusion

Patients that completed Month 36 (Visit 15) of the study B7A-MC-MBCM, and the investigator believes he/she would benefit from ruboxistaurin treatment.

Exclusion

Patients that discontinued from the study B7A-MC-MBCM and/or the investigator does not believe he/she would benefit from ruboxistaurin treatment.

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2008

Estimated Enrollment :

203 Patients enrolled

Trial Details

Trial ID

NCT00266695

Start Date

January 1 2006

End Date

August 1 2008

Last Update

October 6 2016

Active Locations (29)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (29 locations)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test

Mesa, Arizona, United States, 85210

Phoenix, Arizona, United States, 85014

Huntington Beach, California, United States, 92647

Orange, California, United States, 92868

Trial Details

Trial ID

NCT00266695

Start Date

January 1 2006

End Date

August 1 2008

Last Update

October 6 2016

Status: